Testing biomarkers to help diagnose Alzheimer's disease in memory clinic patients
Studies biomarker tests as part of diagnosing Alzheimer's disease in people with memory concerns.
Plain-language title generated from the registry record
Registry title: Biomarkers in a Candian Memory Clinic
Key facts
- Where
- London, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 55 to 80 with mild memory and thinking problems who are being seen at a memory clinic, and who have a study partner.
- Age
- 55 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Mild cognitive impairment (MCI), or memory changes shown on the MoCA test. MoCA score must be 18 to 28.
Main reasons for not taking part
- Memory or thinking problems thought to be caused by something other than Alzheimer's disease
- Down's syndrome, Parkinson's disease, multiple sclerosis or another condition linked to long-term memory loss
- Serious mental illness, or recent psychiatric symptoms that could interfere with the study
- Epilepsy or unexplained blackouts in the past 10 years, or cancer in the past 3 years
- Women who could become pregnant, breastfeeding mothers, or people who cannot give consent
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 80 years old?
Source: NCT06843109, who can take part
Where in Canada
- Parkwood InstituteLondon, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Trial code
- NCT06843109
- Record updated
- 24 February 2025
- Original description
This is a prospective, observational, case control study in a real-world cohort of patients referred by a primary care physician to a tertiary memory clinic for cognitive concerns. This study's main objective is to determine the effect of using standardized criteria (based on eligibility for disease modifying treatment (DMT)) to triage patients towards biological staging of disease with biomarker testing.Read full original descriptionShow less
Biomarkers as Part of Diagnostic Workup for Alzheimer's Disease: A Feasibility Study in a Canadian Memory Clinic
This is a prospective, observational, case control study in a real-world cohort of patients referred by a primary care physician to a tertiary memory clinic for cognitive concerns. This study's main objective is to determine the effect of using standardized criteria (based on eligibility for disease modifying treatment (DMT)) to triage patients towards biological staging of disease with biomarker testing.
Inclusion: Individual with MCI (if not yet diagnosed, individuals with amnestic changes in memory as shown on MoCA); MoCA score must be 18 to 28 inclusive; Age 55 to 80 years inclusive; Has a study partner that is willing to participate as a source of information and has approximately weekly contact with the subject (contact can be in-person, via telephone or electronic communication). The study partner must have sufficient contact such that the investigator feels the study partner can provide meaningful information about the subject's daily function; Group A - must have a clinical memory assessment appointment scheduled at Parkwood Institute within 18 months of baseline; Group B - must have had a clinical memory assessment appointment at Parkwood Institute within 18 months of baseline.
Exclusion: 1) Participants who fulfill diagnostic criteria for MCI or dementia/mild or major neurocognitive disorder suspected to be due to any etiology other than AD (eg, MCI/dementia due to frontotemporal lobar degeneration, diffuse Lewy body disease, Parkinson's disease, cerebrovascular disease, normal pressure hydrocephalus, head injury, drug or alcohol abuse/dependence, anoxic brain injury, etc); Presence of any neurological, psychiatric, or medical conditions associated with a long-term risk of significant cognitive impairment or dementia including, but not limited to, pre-manifest Huntington's disease, multiple sclerosis, Parkinson's disease, Down's syndrome, active alcohol/drug abuse or major psychiatric disorders including, but not limited to, schizophrenia, schizoaffective disorder, or bipolar affective disorder or current episode of major depressive disorder; Current or history within the past 2 years of psychiatric diagnosis or symptoms (eg, hallucinations, major depression, or delusions) that, in the opinion of the investigator, could interfere with study procedures 4) History of epilepsy, fits, or unexplained blackouts other than vasovagal syncope within 10 years before screening; Malignant neoplasms within 3 years (except for basal cell or squamous cell carcinoma in situ of the skin) 6) Women of child bearing potential and breastfeeding mothers 7) Individuals who require sedation to complete PET scan. 8) Individuals who are unable to complete assessments in the English language. 9) Individuals who cannot provide consent.